Please assess the completion status of the following clinical trial:

Trial Title: A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females with type 2 diabetes mellitus (T2DM)~* Are current users of U-100, U-200 and/or U-300 insulin/analog as, basal, premixed and/or basal/bolus delivered with any injection device (pens and/or syringe/vial but excluding continuous subcutaneous infusion (CSII)/insulin pump use in the preceding 3 months), taking a total daily dose (TDD) of greater than or equal to (≥) 150 units (U) or at least one dose greater than (\>) 100 U as part of a multiple daily injection (MDI) regimen and TDD less than or equal to (≤)3.0 units per kilogram (U/kg)~* Concomitant antihyperglycemic agent(s) (AHA) therapy may include: metformin (MET), dipeptidyl peptidase 4 inhibitors, pioglitazone (doses ≤30 milligrams per day (mg/day)), glucagon like peptide (GLP)-1 receptor agonists, sodium-glucose co-transporter-2 (SGLT2) inhibitors, except in combination with GLP-1 receptor agonists~* Participant's antihyperglycemic agent (AHA) therapy must have been stable for ≥3 months (except for weekly GLP-1 receptor agonists which must have been stable for ≥4 months)~* Have hemoglobin A1c (HbA1c) 7.5-11.5 percent (%)~Exclusion Criteria:~* Have type 1 diabetes mellitus (T1DM), or other types of diabetes mellitus apart from T2DM~* Have known hypersensitivities or allergies to insulin, excipients contained in insulin products, or related compounds~* Have used U-500R within 3 months prior to screening~* Have used rosiglitazone, pramlintide, once weekly or twice daily exenatide, or other injectable or oral antihyperglycemic agent(s) not listed in the inclusion criterion; or are taking oral antidiabetic medications at doses exceeding the respective product labels~* Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia which may affect reliability of HbA1c measurements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Part A: U-500R Single Injection (Type: EXPERIMENTAL): Bolus of U-500R administered via single subcutaneous (SC) injection.
- Part A: U-500R CSII (Type: EXPERIMENTAL): Bolus of U-500R administered via continuous subcutaneous insulin infusion (CSII).
- Part B: U-500R TID (Type: EXPERIMENTAL): U-500R administered thrice-daily (TID) via SC injection under steady state conditions for 5 to 10 days
- Part B: U-500R BID (Type: EXPERIMENTAL): U-500R administered twice-daily (BID) via SC injection under steady state conditions for 5 to 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).